 Home > Medical News > Medicines Company News > Bio4T2 announces CAR-T vaccination for the first patient

Bio4T2 announces CAR-T vaccination for the first patient

 Last Update: 2023-02-01
 Source: Internet
 Author: User

Tags

pd 1 therapy

minerals human body

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bio4t2 inoculated the first patient with T cells containing chimeric antigen receptors (CARs), targeting BT-001 antigen overexpression
present in multiple types of solid tumors.
CAR-T (B4t2-001) was developed
by Bio4t2's PrismCore™ platform.

"This first-in-human study marks the evaluation of an initial therapy based on this Bio4t2 technology," said
Laurence Cooper, MD, Executive Chairman of the Board.
"PrismCore's ability to rapidly generate CAR-T that safely targets autoantigens opens up a new frontier
for the provision of CAR-T for the treatment of many types of solid tumors.
This clinical trial is at the forefront of CAR-T biology and provides an avenue for treating a large number of patients with invasive cancers worldwide," added
Dr.
Cooper.

"We are excited to begin clinical trials of the first CAR-T therapy against BT-001, a novel antigen for the therapy," said
Dr.
Farzad Haerizadeh, Chief Scientific Officer and co-founder.
"Our CAR-T was calibrated by PrismCore to distinguish between the level
of BT-001 on tumors and healthy cells.
In fact, B4t2-001 has safely demonstrated potent antitumor activity and long-term protective ability
in preclinical studies in rodents and non-human primates.
This trial helps validate the platform to enable the development of safe and effective CAR-T therapies for multiple types of solid tumors," said
Haerizadeh.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.